Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. GNK
6. HTFL
7. SNDK
8. DVLT
9. ADYYF
10. WDAY

August 10, 2011 8:25 AM EDT
Get Alerts LXRX Hot Sheet
Price: $2.32 -0.85%

Rating Summary:
    3 Buy, 8 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 4 | New: 7
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Lexicon Pharmaceuticals (NASDAQ: LXRX) price target of $3.00.

Needham analyst says, "Lexicon announced encouraging results from a Phase 2 trial of LX1032 in carcinoid syndrome and provided a quarterly update in a conference call earlier today. LX1032 had a greater impact than placebo on both biomarker levels and symptoms. Lexicon plans to meet with the FDA in 4Q11 and may initiate a Phase 3 trial as soon as 2H12. We continue to have a favorable view of the stock and reiterate our rating."

For more ratings news on Lexicon Pharmaceuticals click here and for the rating history of Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $1.40 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Needham & Company